{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T18:15:57Z","timestamp":1759342557206},"reference-count":23,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T00:00:00Z","timestamp":1438819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0134904","type":"journal-article","created":{"date-parts":[[2015,8,6]],"date-time":"2015-08-06T17:55:51Z","timestamp":1438883751000},"page":"e0134904","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates"],"prefix":"10.1371","volume":"10","author":[{"given":"Benoit","family":"Visseaux","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Charpentier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Collin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Bertine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"Damond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Matheron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7oise","family":"Brun-V\u00e9zinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"ANRS CO5 HIV-2 Cohort","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,8,6]]},"reference":[{"key":"ref1","first-page":"139","article-title":"Enfuvirtide, the first fusion inhibitor to treat HIV infection","volume":"7","author":"E Poveda","year":"2005","journal-title":"AIDS Rev"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"14410","DOI":"10.1073\/pnas.222366699","article-title":"Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors","volume":"99","author":"J Ren","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1128\/AAC.01284-07","article-title":"In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors","volume":"52","author":"D Desbois","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.05313-11","article-title":"In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors","volume":"56","author":"B Visseaux","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"ref5","article-title":"Susceptibility of HIV-2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands and small molecule inhibitors","author":"M Esp\u00edrito-Santo","year":"2011","journal-title":"AIDS Research and Human Retroviruses"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3851\/IMP1996","article-title":"Baseline susceptibility of primary HIV-2 to entry inhibitors","volume":"17","author":"P Borrego","year":"2012","journal-title":"Antivir Ther (Lond)"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.antiviral.2010.02.324","article-title":"Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc","volume":"86","author":"D Armstrong-James","year":"2010","journal-title":"Antiviral Res"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jcv.2009.11.008","article-title":"Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure","volume":"47","author":"S Stegmann","year":"2010","journal-title":"J Clin Virol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1093\/jac\/dks240","article-title":"Long-term maraviroc use as salvage therapy in HIV-2 infection","volume":"67","author":"U Caixas","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.virol.2010.09.020","article-title":"Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor","volume":"408","author":"M Calado","year":"2010","journal-title":"Virology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1128\/JVI.73.3.2343-2349.1999","article-title":"Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage","volume":"73","author":"A M\u00f6rner","year":"1999","journal-title":"J Virol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1128\/JVI.79.3.1686-1700.2005","article-title":"CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia","volume":"79","author":"H Blaak","year":"2005","journal-title":"J Virol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1128\/JVI.72.5.4065-4071.1998","article-title":"A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4","volume":"72","author":"A McKnight","year":"1998","journal-title":"J Virol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/08892220252781248","article-title":"CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates","volume":"18","author":"A M\u00f6rner","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1128\/JVI.74.15.6893-6910.2000","article-title":"Use of inhibitors to evaluate coreceptor usage by simian and simian\/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells","volume":"74","author":"Y Zhang","year":"2000","journal-title":"J Virol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/QAI.0b013e318213c2c0","article-title":"Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5\/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects","volume":"57","author":"J Lalezari","year":"2011","journal-title":"J Acquir Immune Defic Syndr"},{"key":"ref17","unstructured":"Gathe J, Cade J, DeJesus E, Feinberg J, Lalezari J, Morales-Ramirez J, et al. Week 24 Primary Analysis of Cenicriviroc vs Efavirenz, in Combination with FTC\/TDF, in Treatment-na\u00efve HIV-1 Infected Adults with CCR5-tropic Virus. 20th Conference on Retroviruses and Opportunistic Infections (CROI), March 2013, Atlanta, GA, USA. Abstract 106LB. Available: http:\/\/www.retroconference.org\/2013b\/abstracts\/48023.htm<\/ext-link>."},{"key":"ref18","unstructured":"Feinberg J, Thompson M, Cade J, DeJesus E, Gathe J, Lalezari J, et al. Final Week 48 Analysis of Cenicriviroc (CVC) Compared to Efavirenz (EFV), in Combination with Emtricitabine\/Tenofovir (FTC\/TDF), in Treatment-Na\u00efve HIV-1-Infected Adults with CCR5-Tropic Virus. 14th European AIDS Conference (EACS), October 2013, Brussels, Belgium. Abstract 202."},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1021\/mp400286s","article-title":"Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound","volume":"10","author":"MM Menning","year":"2013","journal-title":"Mol Pharm"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/jac\/dkn335","article-title":"HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro","volume":"62","author":"B Roquebert","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"ref21","article-title":"Molecular determinants of HIV-2 R5\u2013X4 tropism in the V3 loop: development of a new genotypic tool","author":"B Visseaux","year":"2012","journal-title":"Journal of infectious diseases"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0166-0934(92)90045-F","article-title":"HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase","volume":"37","author":"F Brun-V\u00e9zinet","year":"1992","journal-title":"J Virol Methods"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1128\/AAC.00713-10","article-title":"Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-na\u00efve patients","volume":"55","author":"J-F Marier","year":"2011","journal-title":"Antimicrob Agents Chemother"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0134904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T23:10:07Z","timestamp":1599433807000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0134904"}},"subtitle":[],"editor":[{"given":"Cristian","family":"Apetrei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,8,6]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2015,8,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0134904","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2015,8,6]]}}}